共 93 条
[1]
Averhoff FM(2012)Global burden of hepatitis C: considerations for healthcare providers in the United States Clin Infect Dis 55 S10-S15
[2]
Glass N(2012)HCV burden of infection in Egypt: results from a nationwide survey J Viral Hepat 19 560-567
[3]
Holtzman D(2010)Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis Hepatology 51 388-397
[4]
Guerra J(2014)The rapid evolution of treatment strategies for hepatitis C Am J Gastroenterol 109 628-397
[5]
Garenne M(2014)Sofosbuvir for the treatment of hepatitis C virus Expert Opin Pharmacother 15 121-130
[6]
Mohamed MK(2014)Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection Aliment Pharmacol Ther 39 478-487
[7]
Fontanet A(2015)Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1 N Engl J Med 373 714-725
[8]
Bruno S(2015)All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study Hepatology 61 1127-1135
[9]
Shiffman ML(2016)Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence Hepatology 63 1493-1505
[10]
Roberts SK(2014)Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 211-221